Trevi Therapeutics Announces $150M Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 16 2026
0mins
Source: seekingalpha
- Funding Size: Trevi Therapeutics has announced a public offering of $150 million aimed at supporting the development of Haduvio, its investigational therapy for chronic cough, indicating the company's proactive approach in drug development.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase an additional $22.5 million in shares, a strategy that not only provides extra financial flexibility but may also enhance market demand for its stock.
- R&D Focus: The proceeds will primarily support the development of Haduvio (oral nalbuphine ER), targeting chronic cough symptoms, which highlights Trevi Therapeutics' commitment to addressing this unmet medical need and potentially generating new revenue streams.
- Clinical Trial Plans: Trevi Therapeutics is set to conduct two pivotal Phase III trials focused on IPF-related chronic cough, having achieved alignment with the FDA, which lays a solid foundation for the company's future market access.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRVI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRVI
Wall Street analysts forecast TRVI stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.400
Low
16.00
Averages
21.22
High
25.00
Current: 15.400
Low
16.00
Averages
21.22
High
25.00
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trevi Therapeutics to Attend Multiple Upcoming Events
- Event Schedule: Trevi Therapeutics will participate in the BIO International Convention from June 22-25 in San Diego, California, with CEO Jennifer Good and CCO Farrell Simon attending to showcase their research advancements in chronic cough treatment, aiming to enhance the company's visibility in the biopharmaceutical sector.
- Investor Forum: The company will also attend the Leerink Partners Therapeutics Forum in Boston on July 14-15, represented by CFO David Hastings and CCO Farrell Simon, to attract potential investors' interest in their R&D projects.
- Cough Conference: Trevi will present at the ERS Cough Conference in London from July 15-17, where CEO Jennifer Good and CDO James Cassella will discuss the clinical trial results of Haduvio™, emphasizing its unique advantages in treating chronic cough.
- Market Demand: Chronic cough is prevalent among patients with idiopathic pulmonary fibrosis and non-IPF interstitial lung disease, with approximately 140,000 U.S. patients affected, positioning Trevi's Haduvio™ as the only investigational therapy with significant market potential to address this unmet medical need.
See More
Pivotal Increases Stake in Trevi Therapeutics
- Increased Holdings: Pivotal bioVenture Partners increased its stake in Trevi Therapeutics by 296,944 shares during Q1 2026, with an estimated transaction value of $3.32 million, indicating confidence in the company's future prospects.
- Value Appreciation: By the end of the quarter, Pivotal held a total of 1,553,726 shares valued at $18.54 million, reflecting a $2.80 million increase due to both stock price appreciation and new purchases, showcasing strong market performance.
- Outstanding Market Performance: As of May 13, 2026, Trevi Therapeutics shares were priced at $15.27, representing a 136.4% increase over the past year, significantly outperforming the S&P 500 by 109.92 percentage points, highlighting strong market recognition of its products.
- Investment Risks and Opportunities: While Pivotal's increased stake is seen as validation of Trevi's scientific progress, the risks of clinical trial failures and market competition remain, making it suitable for investors with a high-risk tolerance.
See More
Trevi Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Initiation: Trevi Therapeutics plans to initiate two studies related to idiopathic pulmonary fibrosis (IPF) chronic cough in Q1 2026, with the second study expected to start in the second half of the year, which will enhance the company's competitive position in the chronic cough market.
- Improved Financial Position: As of the end of Q1 2026, the company reported approximately $172 million in cash and cash equivalents, and the $162 million net proceeds from the April 2026 equity offering will extend the cash runway into 2030, alleviating financial pressure.
- R&D Strategy Adjustment: Management has decided to shift the study design for non-IPF-ILD chronic cough to an adaptive Phase II/III study, with plans to submit the protocol to the FDA in the second half of the year, which will help improve the likelihood of clinical trial success.
- Market Outlook: Management emphasized a focus on trial initiations and interim milestones rather than revenue or EPS guidance, reflecting the company's confidence in execution and capitalization, particularly regarding the upcoming RCC Phase IIb trial and SSRE results release.
See More
Trevi Therapeutics Q1 Earnings Report Analysis
- Earnings Miss: Trevi Therapeutics reported a Q1 non-GAAP EPS of -$0.09, missing expectations by $0.02, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of Q1 2026, the company held $171.8 million in cash, cash equivalents, and marketable securities, ensuring operational funding for the coming years despite ongoing profitability issues.
- Funding Impact: Following the completion of its underwritten common stock offering in April 2026, Trevi expects its current cash resources to extend its runway into 2030, providing essential financial support for future R&D and operational needs.
- Clinical Trial Plans: Trevi is planning two pivotal phase III trials for IPF-related chronic cough, and while execution risks remain, FDA alignment offers confidence for its future development.
See More
Trevi Therapeutics Prices $150 Million Public Offering Amid Bullish Market Sentiment
- Successful Public Offering: Trevi Therapeutics priced its $150 million public offering at $13 per share, planning to issue 11.6 million shares, with the offering expected to close around April 20, 2026, indicating strong market confidence in its future prospects.
- Stock Price Surge: Following the public offering announcement, Trevi's shares jumped 5% on Friday to an all-time high, with nearly a 20% increase over the past five trading sessions, reflecting investor optimism about the company's potential growth.
- Clinical Trial Plans: Trevi plans to launch two late-stage clinical trials for its chronic cough treatment Haduvio in the second quarter of 2026, with the first trial enrolling around 300 patients and the second about 130, aimed at validating the drug's safety and efficacy.
- Market Sentiment Shift: According to Stocktwits data, retail investor sentiment flipped from 'bearish' to 'bullish' a day before the offering, with message volumes soaring 600%, demonstrating strong market interest and confidence in Trevi's future developments.
See More
Trevi Therapeutics Prices Public Offering at $13 per Share
- Public Offering Pricing: Trevi Therapeutics announced the pricing of 11,600,000 shares at $13 each, expecting to raise $150 million, which will bolster its financial position in the biopharmaceutical sector.
- Stock Performance: Following the announcement, Trevi's shares reached a 52-week high of $14.75, reflecting positive market sentiment towards its new therapy, although pre-market trading saw a decline to $13.88, down 4.54%.
- Underwriter Option: Underwriters have a 30-day option to purchase an additional 1,740,000 shares at the public offering price, enhancing the company's fundraising capabilities to support its research projects.
- R&D Progress: Trevi is developing Haduvio (oral nalbuphine extended release), the first investigational therapy showing significant efficacy in clinical trials for idiopathic pulmonary fibrosis and refractory chronic cough, indicating substantial market potential.
See More
Trevi Therapeutics to Attend Multiple Upcoming Events
- Event Schedule: Trevi Therapeutics will participate in the BIO International Convention from June 22-25 in San Diego, California, with CEO Jennifer Good and CCO Farrell Simon attending to showcase their research advancements in chronic cough treatment, aiming to enhance the company's visibility in the biopharmaceutical sector.
- Investor Forum: The company will also attend the Leerink Partners Therapeutics Forum in Boston on July 14-15, represented by CFO David Hastings and CCO Farrell Simon, to attract potential investors' interest in their R&D projects.
- Cough Conference: Trevi will present at the ERS Cough Conference in London from July 15-17, where CEO Jennifer Good and CDO James Cassella will discuss the clinical trial results of Haduvio™, emphasizing its unique advantages in treating chronic cough.
- Market Demand: Chronic cough is prevalent among patients with idiopathic pulmonary fibrosis and non-IPF interstitial lung disease, with approximately 140,000 U.S. patients affected, positioning Trevi's Haduvio™ as the only investigational therapy with significant market potential to address this unmet medical need.
See More
Pivotal Increases Stake in Trevi Therapeutics
- Increased Holdings: Pivotal bioVenture Partners increased its stake in Trevi Therapeutics by 296,944 shares during Q1 2026, with an estimated transaction value of $3.32 million, indicating confidence in the company's future prospects.
- Value Appreciation: By the end of the quarter, Pivotal held a total of 1,553,726 shares valued at $18.54 million, reflecting a $2.80 million increase due to both stock price appreciation and new purchases, showcasing strong market performance.
- Outstanding Market Performance: As of May 13, 2026, Trevi Therapeutics shares were priced at $15.27, representing a 136.4% increase over the past year, significantly outperforming the S&P 500 by 109.92 percentage points, highlighting strong market recognition of its products.
- Investment Risks and Opportunities: While Pivotal's increased stake is seen as validation of Trevi's scientific progress, the risks of clinical trial failures and market competition remain, making it suitable for investors with a high-risk tolerance.
See More
Trevi Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Initiation: Trevi Therapeutics plans to initiate two studies related to idiopathic pulmonary fibrosis (IPF) chronic cough in Q1 2026, with the second study expected to start in the second half of the year, which will enhance the company's competitive position in the chronic cough market.
- Improved Financial Position: As of the end of Q1 2026, the company reported approximately $172 million in cash and cash equivalents, and the $162 million net proceeds from the April 2026 equity offering will extend the cash runway into 2030, alleviating financial pressure.
- R&D Strategy Adjustment: Management has decided to shift the study design for non-IPF-ILD chronic cough to an adaptive Phase II/III study, with plans to submit the protocol to the FDA in the second half of the year, which will help improve the likelihood of clinical trial success.
- Market Outlook: Management emphasized a focus on trial initiations and interim milestones rather than revenue or EPS guidance, reflecting the company's confidence in execution and capitalization, particularly regarding the upcoming RCC Phase IIb trial and SSRE results release.
See More
Trevi Therapeutics Q1 Earnings Report Analysis
- Earnings Miss: Trevi Therapeutics reported a Q1 non-GAAP EPS of -$0.09, missing expectations by $0.02, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of Q1 2026, the company held $171.8 million in cash, cash equivalents, and marketable securities, ensuring operational funding for the coming years despite ongoing profitability issues.
- Funding Impact: Following the completion of its underwritten common stock offering in April 2026, Trevi expects its current cash resources to extend its runway into 2030, providing essential financial support for future R&D and operational needs.
- Clinical Trial Plans: Trevi is planning two pivotal phase III trials for IPF-related chronic cough, and while execution risks remain, FDA alignment offers confidence for its future development.
See More
Trevi Therapeutics Prices $150 Million Public Offering Amid Bullish Market Sentiment
- Successful Public Offering: Trevi Therapeutics priced its $150 million public offering at $13 per share, planning to issue 11.6 million shares, with the offering expected to close around April 20, 2026, indicating strong market confidence in its future prospects.
- Stock Price Surge: Following the public offering announcement, Trevi's shares jumped 5% on Friday to an all-time high, with nearly a 20% increase over the past five trading sessions, reflecting investor optimism about the company's potential growth.
- Clinical Trial Plans: Trevi plans to launch two late-stage clinical trials for its chronic cough treatment Haduvio in the second quarter of 2026, with the first trial enrolling around 300 patients and the second about 130, aimed at validating the drug's safety and efficacy.
- Market Sentiment Shift: According to Stocktwits data, retail investor sentiment flipped from 'bearish' to 'bullish' a day before the offering, with message volumes soaring 600%, demonstrating strong market interest and confidence in Trevi's future developments.
See More
Trevi Therapeutics Prices Public Offering at $13 per Share
- Public Offering Pricing: Trevi Therapeutics announced the pricing of 11,600,000 shares at $13 each, expecting to raise $150 million, which will bolster its financial position in the biopharmaceutical sector.
- Stock Performance: Following the announcement, Trevi's shares reached a 52-week high of $14.75, reflecting positive market sentiment towards its new therapy, although pre-market trading saw a decline to $13.88, down 4.54%.
- Underwriter Option: Underwriters have a 30-day option to purchase an additional 1,740,000 shares at the public offering price, enhancing the company's fundraising capabilities to support its research projects.
- R&D Progress: Trevi is developing Haduvio (oral nalbuphine extended release), the first investigational therapy showing significant efficacy in clinical trials for idiopathic pulmonary fibrosis and refractory chronic cough, indicating substantial market potential.
See More
